Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.64 |
| ▸ | MEN1 | O00255 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.60 |
| ▸ | GAA | P10253 | 4/20 | 0.60 |
| ▸ | RAB9A | P51151 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL728396 | 0.89 | POLB (0.68) | POLBKMT2AMEN1ALDH1A1GAA | |
| SCHEMBL19425598 | 0.82 | POLB (0.74) | POLBKMT2AMEN1ALDH1A1GAA | |
| SCHEMBL15702626 | 0.82 | POLB (0.78) | POLBKMT2AMEN1ALDH1A1GAA | |
| SCHEMBL20009934 | 0.82 | POLB (1.00) | POLBKMT2AMEN1ALDH1A1GAA | |
| SCHEMBL7822057 | 0.82 | POLB (0.74) | POLBKMT2AMEN1ALDH1A1GAA | |
| SCHEMBL19425502 | 0.80 | POLB (0.75) | POLBKMT2AMEN1ALDH1A1GAA | |
| SCHEMBL20705655 | 0.80 | POLB (0.75) | POLBKMT2AMEN1ALDH1A1GAA | |
| SCHEMBL5862372 | 0.80 | POLB (0.75) | POLBKMT2AMEN1ALDH1A1GAA | |
| SCHEMBL15702588 | 0.79 | POLB (0.74) | POLBKMT2AMEN1ALDH1A1GAA | |
| SCHEMBL728496 | 0.79 | POLB (0.74) | POLBKMT2AMEN1ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110319454-A1 | DERIVATIVES OF CYCLOALKYL- AND CYCLOALKENYL-1,2-DICARBOXYLIC ACID COMPOUNDS HAVING FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) AGONIST OR ANTAGONIST ACTIVITY | ALLERGAN, INC. (US) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319454-A1 | DERIVATIVES OF CYCLOALKYL- AND CYCLOALKENYL-1,2-DICARBOXYLIC ACID COMPOUNDS HAVING FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) AGONIST OR ANTAGONIST ACTIVITY | FPR1, FPR2, FPR3 | POLB 4020/4885KMT2A 4493/4885MEN1 2722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.